Regional knowledge capabilities, embeddedness of firms and industry organisation: Bioscience megacentres and economic geography

Abstract

Changes in epistemology in biosciences are generating important spatial effects. The most notable of these is the emergence of a few 'Bioscience Megacentres' for basic and applied bioscience medical and clinical research (molecular, post-genomic, proteomics, etc.), biotechnology research, training in these and related fields, academic entrepreneurship and commercial exploitation by clusters of 'drug discovery' start-up and spin-off companies, along with specialist venture capital and other innovation system support services. Large pharmaceutical firms that used to lead such knowledge generation and exploitation processes are becoming increasingly dependent upon innovative drug solutions produced in such clusters, and megacentres are now the predominant source of such commercial knowledge. 'Big pharma' is seldom at the heart of megacentres such as those the paper will argue are found in about four locations each in the USA and Europe, but remains important for some risk capital ('milestone payments'), marketing, and distribution of drugs discovered. The embedding of these processes also creates major new regional disparities, which some regional governances have recognised, causing them to develop responsibilities for regional science policy and funding to offset spatial biases intrinsic in traditional national (and in the EU, supranational) research funding regimes. Responses follow a variety of models ranging from market-following to both regionalised (decentralising by the centre) and 'regionalist' (ground-up); in each case, the role of megacentres is justified in health terms. But their role in assisting fulfilment of regional economic growth visions is also clearly perceived and pronounced in policy terms.